Fever-Tree

Ticker: FEVR LN

Sector: Spirits

Rating: Buy

Published Research

Fever-Tree: ~20% Rebound on EBITDA Expectations … and Margot Robbie? (March 2025)

Fever-Tree: Solving U.S. Strategic Problem, Likely at the Right Price (February 2025)

Fever-Tree: H1 Showed Costs are On Track, Even if Growth is Not (Yet) (September 2024)

Fever-Tree: Long-Term Compounder; Takeover Potential Not Priced In (Initiation) (June 2024)